Evaluation of the effect of full mouth disinfection therapy on the recurrence of Helicobacter pylori infection

Evaluation of the effect of full mouth disinfection therapy on the recurrence of Helicobacter pylori infection in patients referred to Sayad shirazi hospital in Gorgan

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017080530744N2

Enrollment

Registered

2017-10-24

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stomach ulcer caused by Helicobacter pylori. -disease of stomach

Interventions

Intervention 1: Intervention group: Routine treatment of Helicobacter pylori including bismuth tablet 525 mg (hepatica-Iran) 4 times a day for 2 weeks, Clarithromycin 500 mg tablet (Tehran Chem-Iran)

Treatment - Other

Treatment - Drugs

Intervention group: Routine treatment of Helicobacter pylori including bismuth tablet 525 mg (hepatica-Iran) 4 times a day for 2 weeks, Clarithromycin 500 mg tablet (Tehran Chem-Iran) twice a day for

Intervention in the control : Routine drug treatment of Helicobacter pylori , including bismuth tablet 525 mg (healing-Iran) 4 times a day For 2 weeks, Clarithromycin Tablet 250 mg (Tehran Chem. Ir

Eligibility

Sex/Gender

All

Age

99 Years to 57 Years

Inclusion criteria

Inclusion criteria: Major entry requirements: People older than 18 years; at least 10 teeth with the exception of remaining roots and wisdom teeth; gingival index less than 3 mm; pocket depth less than or equal to 4 mm; attachment loss less than 5 mm. Patient withdrawal conditions from the study : Consumption of antibiotic or proton pump inhibitor in the past month; Radiation therapy patients; Patients with a history of sensitivity to amoxicillin, clarithromycin, bismuth, omeprazole and chlorhexidine; Patients who once received systemic Helicobacter pylori infection therapy ; Patients with systemic diseases; Pregnant and nursing mothers; smoking

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori induced gastritis. Timepoint: at baseline. Method of measurement: Urease test and expert opinion.	—

Secondary

Measure	Time frame
-recurrence of helicobacter induced gastritis. Timepoint: -4 months after treatment. Method of measurement: -respiratory urease test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Elham Fakhari

Faculty of dentistry, Golestan University of Medical Sciences

dr.fakhari@goums.ac.ir+98 17 3255 5700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026